DUBLIN, January 21, 2022--(BUSINESS WIRE)--The "Oncology Molecular Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
The oncology molecular diagnostics market is expected to register a CAGR of more than 12 % during the forecast period.
F-Hoffmann La-Roche Ltd
Becton, Dickinson and Company
Danaher Corporation (Cepheid)
Sysmex Corporation (Sysmex Europe GmbH)
Thermo Fisher Scientific Inc.
Agilient Technologies, Inc. (Dako)
TBG Diagnostics Limited
HTG Molecular Diagnostics, Inc.
Key Market Trends
Polymerase Chain Reaction (PCR) is Anticipated to Observe a Significant Growth
Based on technology, polymerase chain reaction (PCR) is anticipated to witness significant growth. Presently, the polymerase chain reaction (PCR) is the most preferred technology for studying cancer. The major factors contributing to the increasing demand for PCR in oncology molecular diagnostics are greater sensitivity, quantification, ease, precision, and reproducibility, better process quality, fast analysis, and lower risk of contamination.
It is a sensitive and rapid technique and is ideal for the detection of lymphoid malignancies. Several manufacturers are engaged in developing PCR-based diagnostic instruments and reagents for the detection of cancer.
For instance, in June 2021, the AmoyDx Pan Lung Cancer PCR Panel was launched by Amoy Diagnostics Co., Ltd., Riken Genesis Co., Ltd., and Precision Medicine Asia Co., Ltd. It is approved by the Ministry of Health, Labour and Welfare (MHLW) for marketing and production in Japan. Thus, in view of the aforementioned factors, the market is anticipated to grow significantly over the forecast period.
North America is Anticipated to Observe a Significant Growth in Oncology Molecular Diagnostics Market
Within North America, the United States has held a major share of the market. The major factors contributing to the market growth are the presence of many market players engaged in manufacturing and expanding the portfolio of instruments and reagents for molecular diagnostic testing. The region also witnesses the presence of well-established healthcare diagnostic facilities.
As per a 2020 report by the American Cancer Society, several professional associations, including the National Comprehensive Cancer Network (NCCN), the American Association of Clinical Oncology (ASCO), and the College of American Pathologists (CAP) have developed biomarker testing and treatment guidelines. Additionally, the increasing prevalence of cancer in the country is contributing to the oncology molecular diagnostics market in the region.
As per the 2020 Statistics by the National Cancer Institute (NCI), about 1,806,590 cases of cancer were diagnosed in the United States in 2020 and the number of cancer survivors is projected to reach 2.2 million by 2030. Moreover, as per the NCI, in 2021, the most prevalent cancer type is breast cancer with 284,200 cases. These factors are leading to an increased demand for oncology molecular testing in the region. Thus, in view of the aforementioned factors, the market will witness a significant growth in the region over the forecast period.
Key Topics Covered:
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Cancer Worldwide
4.2.2 Technological Advancements in Diagnostic Testing
4.2.3 Increasing Demand for Point-Of-Care Treatment
4.3 Market Restraints
4.3.1 High Cost of Molecular Diagnostic Tests
4.3.2 Lack of Skilled Workforce and Stringent Regulatory Framework
4.4 Porter's Five Force Analysis
5 MARKET SEGMENTATION
5.1 Product Type
5.2 Technology Type
5.3 Application Type
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/uuqxu7
View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005335/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900